Select Medical Holdings (SEM) shareholders have formally approved the buyout by a private investor consortium, removing one of the last major hurdles between the current share price and the deal closing price. The company reported FY revenue of $5.5B (+5.1% YoY) with a thin 3.9% net margin and $1.16 diluted EPS — a profile consistent with a capital-intensive healthcare services operator.

With stockholder approval in hand, the remaining risk events are regulatory clearance and financing closing conditions. Deals of this type in healthcare services have faced antitrust scrutiny at times, though specialized hospital and rehab networks have generally had a smoother path than acute-care consolidations.

For market participants, SEM is now a classic merger-arb setup: the trade is long SEM vs. the announced deal price, with the spread representing time value and residual deal-break risk. The narrower the spread, the less upside remains — but also the lower the implied probability the market is assigning to a break.

Key items to watch: the precise deal price vs. current trading level (the spread), any regulatory filing deadlines, and whether there are any financing commitment expirations that could reintroduce uncertainty. If macro credit conditions tighten materially, leveraged buyout financing risk re-emerges as a tail risk.